IL241937B - Metastasis inhibitors - Google Patents

Metastasis inhibitors

Info

Publication number
IL241937B
IL241937B IL241937A IL24193715A IL241937B IL 241937 B IL241937 B IL 241937B IL 241937 A IL241937 A IL 241937A IL 24193715 A IL24193715 A IL 24193715A IL 241937 B IL241937 B IL 241937B
Authority
IL
Israel
Prior art keywords
metastasis
inhibitors
Prior art date
Application number
IL241937A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ North Carolina State
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State, Biomarck Pharmaceuticals Ltd filed Critical Univ North Carolina State
Publication of IL241937B publication Critical patent/IL241937B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
IL241937A 2013-04-05 2015-10-06 Metastasis inhibitors IL241937B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (1)

Publication Number Publication Date
IL241937B true IL241937B (en) 2019-03-31

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241937A IL241937B (en) 2013-04-05 2015-10-06 Metastasis inhibitors

Country Status (19)

Country Link
US (4) US9408886B2 (enExample)
EP (1) EP2981279B1 (enExample)
JP (1) JP6449849B2 (enExample)
KR (1) KR102191695B1 (enExample)
CN (1) CN105517562B (enExample)
AU (1) AU2014247979B2 (enExample)
BR (1) BR112015025398A2 (enExample)
CA (1) CA2908832C (enExample)
DK (1) DK2981279T3 (enExample)
ES (1) ES2714863T3 (enExample)
HU (1) HUE043971T2 (enExample)
IL (1) IL241937B (enExample)
MX (1) MX363077B (enExample)
PL (1) PL2981279T3 (enExample)
PT (1) PT2981279T (enExample)
RU (1) RU2681213C2 (enExample)
SG (2) SG10201708125PA (enExample)
WO (1) WO2014165853A1 (enExample)
ZA (1) ZA201508010B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708125PA (en) 2013-04-05 2017-11-29 Biomarck Pharmaceuticals Ltd Inhibitors of metastasis
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
PT1411967E (pt) 2001-06-26 2011-09-30 Univ North Carolina State Péptido bloqueador que atua sobre a secreção de células inflamatórias
JP2005523879A (ja) * 2001-10-05 2005-08-11 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Sirs/sepsisを治療及び予防するための組成物及び方法
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
WO2008127355A2 (en) * 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
KR20090086415A (ko) 2006-10-27 2009-08-12 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 전이성 결장직장 암에 대한 검정
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
SG10201708125PA (en) 2013-04-05 2017-11-29 Biomarck Pharmaceuticals Ltd Inhibitors of metastasis

Also Published As

Publication number Publication date
MX363077B (es) 2019-03-07
SG11201508249WA (en) 2015-11-27
AU2014247979A1 (en) 2015-10-29
CN105517562A (zh) 2016-04-20
CA2908832A1 (en) 2014-10-09
ZA201508010B (en) 2017-01-25
KR102191695B1 (ko) 2020-12-16
HUE043971T2 (hu) 2019-09-30
US10011636B2 (en) 2018-07-03
JP2016516756A (ja) 2016-06-09
MX2015014036A (es) 2016-02-25
SG10201708125PA (en) 2017-11-29
RU2681213C2 (ru) 2019-03-05
EP2981279A4 (en) 2016-11-09
WO2014165853A1 (en) 2014-10-09
NZ712955A (en) 2021-03-26
RU2015146997A (ru) 2017-05-15
KR20150140736A (ko) 2015-12-16
CN105517562B (zh) 2018-12-28
PL2981279T3 (pl) 2019-09-30
US10683328B2 (en) 2020-06-16
US20170121369A1 (en) 2017-05-04
ES2714863T3 (es) 2019-05-30
BR112015025398A2 (pt) 2017-10-10
US20210130403A1 (en) 2021-05-06
RU2015146997A3 (enExample) 2018-03-13
HK1221159A1 (en) 2017-05-26
AU2014247979B2 (en) 2018-06-28
CA2908832C (en) 2023-01-24
US20190119320A1 (en) 2019-04-25
JP6449849B2 (ja) 2019-01-09
PT2981279T (pt) 2019-03-14
EP2981279B1 (en) 2018-12-19
US9408886B2 (en) 2016-08-09
EP2981279A1 (en) 2016-02-10
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
DK2981279T3 (en) 2019-03-25

Similar Documents

Publication Publication Date Title
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
PT3305778T (pt) Inibidores de calicreína plasmática
SI3080100T1 (sl) Inhibitorji lizin specifične demetilaze-1
HUE14755117T2 (hu) Plazma-kallikrein inhibitorok
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
ZA201506516B (en) Hdac inhibitors
IL265496A (en) bace1 inhibitors
ZA201506156B (en) Novel inhibitors
IL245245A0 (en) New dgat2 inhibitors
IL244617A0 (en) Benzoquinolone compounds as vmat2 inhibitors
EP2994124A4 (en) INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
ZA201508010B (en) Inhibitors of metastasis
ZA201507100B (en) Synthesis of bace1 inhibitors
GB201312311D0 (en) Uses of enzyme inhibitors
EP2959896A4 (en) INHIBITOR OF PHOSPHORYLATION OF PROTEIN T
GB201320835D0 (en) HIF inhibitors
GB201305503D0 (en) Inhibitor
GB201318284D0 (en) Construction of surfaces

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed